Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
Neoadjuvant therapy in melanoma: a new standard of care. 黑色素瘤的新辅助治疗:一种新的护理标准。
IF 1.1
Nikhil I Khushalani
{"title":"Neoadjuvant therapy in melanoma: a new standard of care.","authors":"Nikhil I Khushalani","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"423-426"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted immunotherapy in the treatment of childhood and adolescent mature B-cell lymphoma. 靶向免疫疗法治疗儿童和青少年成熟b细胞淋巴瘤。
IF 1.1
Anthony N Audino, Aliza Gardenswartz, Mitchell S Cairo
{"title":"Targeted immunotherapy in the treatment of childhood and adolescent mature B-cell lymphoma.","authors":"Anthony N Audino, Aliza Gardenswartz, Mitchell S Cairo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mature B-cell non-Hodgkin lymphomas (B-NHLs) comprise approximately 40% to 60% of all NHLs among children, adolescents, and young adults. Although overall survival with mature B-NHL approaches 90% in children younger than 15 years and 70% to 80% in adolescents and young adults, it is achieved with the use of intense therapeutic regimens, many of which lead to long-term effects that last for years after the patient's initial diagnosis and treatment. Chronic health issues, poor performance outcomes, impaired quality of life, and decreased fertility have all been associated with mature B-NHL therapy. As the role of targeted therapy in this population is elucidated, data continue to show that it can be incorporated safely into chemotherapy backbones, allowing a decrease in cytotoxic chemotherapy doses. These trends support ongoing efforts to find innovative combinatorial strategies that integrate new cell surface targets and use new classes of drugs, such as monoclonal antibodies, antibody-drug conjugates, checkpoint inhibitors, T-cell and natural killer-cell engagers, and chimeric antigen receptor T-cell therapy.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"436-445"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting prostate-specific membrane antigen in prostate cancer. 靶向前列腺特异性膜抗原在前列腺癌中的作用。
IF 1.1
Louise Emmett
{"title":"Targeting prostate-specific membrane antigen in prostate cancer.","authors":"Louise Emmett","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"413-415"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of antibody-drug conjugates in gynecologic cancers. 抗体-药物偶联物在妇科癌症中的应用。
IF 1.1
Joyce F Liu
{"title":"The use of antibody-drug conjugates in gynecologic cancers.","authors":"Joyce F Liu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"410-412"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer and cardiovascular health: a multidisciplinary approach. 癌症和心血管健康:多学科方法。
IF 1.1
Susan Dent
{"title":"Cancer and cardiovascular health: a multidisciplinary approach.","authors":"Susan Dent","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Early detection and improved cancer therapies have led to increases in cancer survivorship. There were 18.1 million cancer survivors in the United States alone in 2022, and this number will grow to 21.6 million by 2030. Cancer survivors are at increased risk for non-cancer-related morbidity and mortality, including cardiovascular disease. Cardio-oncology has emerged as a new subspecialty of medicine, dedicated to improving the cardiovascular health of patients with cancer and facilitating the administration of the best cancer therapy while optimizing cardiovascular health. Contemporary cancer treatments are associated with multiple types of cancer treatment-related cardiac dysfunction (CTRCD), including heart failure, vascular toxicities, arrhythmias/corrected QT prolongation, hypertension, and myocarditis. In 2022, the European Society of Cardiology published comprehensive guidelines that endorsed the Heart Failure Association/International Cardio-Oncology Society baseline risk stratification tool for assessing all patients with cancer before cancer therapy is started. Primary prevention strategies can be considered for patients at high risk and very high risk for CTRCD, with the goal of facilitating the delivery of cancer therapy while minimizing the risk of cardiovascular toxicity. Dedicated multidisciplinary cardio-oncology clinics have emerged across North America, Europe, South America, Asia, South Africa, and Australia to enhance cancer care while optimizing cardiovascular health.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"446-452"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using imetelstat for lower-risk myelodysplastic syndromes. 使用依美特司他治疗低风险骨髓增生异常综合征。
IF 1.1
Valeria Santini
{"title":"Using imetelstat for lower-risk myelodysplastic syndromes.","authors":"Valeria Santini","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 7","pages":"432-434"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and treatment of secondary hemophagocytic lymphohistiocytosis in adults. 成人继发性噬血细胞淋巴组织细胞病的诊断与治疗。
IF 1.1
Bita Shakoory, Joseph M Rocco
{"title":"Diagnosis and treatment of secondary hemophagocytic lymphohistiocytosis in adults.","authors":"Bita Shakoory, Joseph M Rocco","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 6","pages":"388-391"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is there a universal standard of care for frontline therapy in multiple myeloma? 对于多发性骨髓瘤的一线治疗是否有一个通用的护理标准?
IF 1.1
Sagar Lonial
{"title":"Is there a universal standard of care for frontline therapy in multiple myeloma?","authors":"Sagar Lonial","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 6","pages":"379-381"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Midyear highlights in gastrointestinal cancers: expert perspectives. 胃肠癌的年中亮点:专家观点。
IF 1.1
Tanios S Bekaii-Saab, David H Ilson
{"title":"Midyear highlights in gastrointestinal cancers: expert perspectives.","authors":"Tanios S Bekaii-Saab, David H Ilson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 Suppl 9 6","pages":"4-15"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emerging role of antibody-drug conjugates in metastatic colorectal cancer. 抗体-药物结合物在转移性结直肠癌中的新作用。
IF 1.1
John H Strickler
{"title":"The emerging role of antibody-drug conjugates in metastatic colorectal cancer.","authors":"John H Strickler","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 6","pages":"385-387"},"PeriodicalIF":1.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信